APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

NCT02850289 · clinicaltrials.gov ↗

COMPLETED

Status

385

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Pegylated interferon (PEG-INF) alfa-2a
DRUG: Ribavirin

Sponsor

Hoffmann-La Roche